ArticleOncology letters2021

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression.

Kazuya Nishii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.